158 results
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Doctors at the National Institutes of Health (NIH) seek patients with thyroid cancer that spread outside the thyroid - to the lymph nodes, lungs or bones. The standard treatment in such situation is therapy with radioactive iodine (RAI). In this study, doctors will assess a new imaging tool - 124I PET/CT, which enables evaluation of how much iodine goes into the tumor. The study goal is to compare how much iodine goes into cancer cells after two different methods of stimulation of RAI uptake.
Learn More
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance
Doctors at the National Institutes of Health (NIH) are conducting a study on patients with clonal hematopoiesis of indeterminate potential (CHIP). Patients with CHIP have a genetic mutation that has been associated with blood cancer. The study will look at CHIP and try to determine its relationship to blood cancers and heart disease. The study will also try to discover other new organs or diseases that may be linked with.
Learn More
Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)
The research study sets out to learn about changes in the genetic makeup of CLL during the early phase of treatment with venetoclax. The initial phase of venetoclax therapy can be medically and logistically challenging. Patients will receive expert medical care at the National Institutes of Health (NIH).
Learn More
Men at High Genetic Risk for Prostate Cancer
Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Learn More
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) (En español)
Are you looking for a treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)? Researchers at the National Institutes of Health (NIH) seek volunteers to participate in a research study. For 30 weeks, participants will receive a medication called semaglutide (typically used for Type 2 diabetes), aiming to improve their liver disease and help them lose weight. The study hopes to better understand liver damage and its treatment in people with these conditions. (En español)
Learn More